Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ARF-BP1 as a potential therapeutic target.

D Chen1, C L Brooks, W Gu

  • 1Institute for Cancer Genetics, Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA.

British Journal of Cancer
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.

Leukemia·2017
Same author

Conformational Sampling of Maltose-transporter Components in Cartesian Collective Variables is Governed by the Low-frequency Normal Modes.

The journal of physical chemistry letters·2012
Same author

Inactivation of HAUSP in vivo modulates p53 function.

Oncogene·2009
Same author

CHARMM: the biomolecular simulation program.

Journal of computational chemistry·2009
Same author

The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP.

Oncogene·2007
Same author

Effects of an S84E mutation of bovine growth hormone in transgenic mice.

Experimental biology and medicine (Maywood, N.J.)·2006

ARF-BP1, an E3 ubiquitin ligase, regulates p53 stability and apoptosis. Inhibiting ARF-BP1 offers a promising new cancer therapy strategy, effective even in p53-deficient tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9) is a recently identified HECT domain-containing E3 ubiquitin ligase.
  • ARF-BP1 interacts with tumor suppressors ARF and p53.
  • The E3 ubiquitin ligase activity of ARF-BP1 is regulated by ARF.

Purpose of the Study:

  • To review the role of ARF-BP1 in cancer.
  • To explore ARF-BP1 as a potential therapeutic target.

Main Methods:

  • Literature review of ARF-BP1 function.
  • Analysis of ARF-BP1 interactions with ARF and p53.
  • Investigation of ARF-BP1's impact on p53 stability and apoptosis.

Main Results:

Related Experiment Videos

  • ARF inhibits the ubiquitin ligase activity of ARF-BP1.
  • Inactivation of ARF-BP1 leads to p53 stabilization and apoptosis induction.
  • ARF-BP1 inactivation suppresses tumor growth in p53-null and mutant p53 cancer cells.

Conclusions:

  • ARF-BP1 is a critical regulator of p53.
  • Targeting ARF-BP1 represents a novel therapeutic strategy for various cancers, irrespective of p53 status.